Wave Life Sciences, Inc.

As of June 30, 2026, Wave Life Sciences Inc carries a market capitalization of 984.82M, placing it among publicly traded companies globally. Its enterprise value stands at 593.55M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Wave Life Sciences Inc's next confirmed earnings release is scheduled for October 27, 2026.

As of June 30, 2026, Wave Life Sciences Inc has 193.10M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 16.74, and the price-to-book ratio stands at 2.48.

These figures are as of June 30, 2026. The EV/Sales ratio of 10.37 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 593.55M versus a market cap of 984.82M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Wave Life Sciences Inc maintains a current ratio of 9.99, meaning it holds 10.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Wave Life Sciences Inc posted a negative return on equity (ROE) of -68.31, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -49.95, reflecting losses generated across the asset base. The company generates approximately 184,727.16 in revenue per employee across its workforce of 309.75, a quick read on workforce productivity versus industry peers.

As of the close on August 10, 2026, Wave Life Sciences Inc's stock has declined approximately 23.91% over the past 52 weeks. The 50-day moving average sits at 5.18, while the 200-day moving average is 8.06.

Over the twelve months ended June 30, 2026, Wave Life Sciences Inc generated 57.22M in revenue and converted that into -177.22M in net income, yielding earnings per share of -0.94. EBITDA reached -182.72M, while operating income came in at -190.75M.

As of June 30, 2026, Wave Life Sciences Inc holds 429.42M in cash and equivalents against 38.15M in total debt, resulting in a net debt position of -322.12M. Total book value stands at 396.97M, with working capital of 399.74M providing operational flexibility.

Wave Life Sciences Inc produced -167.69M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.37M in capital expenditures, free cash flow totaled -169.06M - equivalent to -0.90 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -333.36 and net profit margin of -309.73 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -17.65: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -42.24, meaning Wave Life Sciences Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Wave Life Sciences Inc has an Altman Z-Score of 2.69, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.